New research reveals that people who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional diet and exercise plans.
Published data in a leading health publication shows that while obese individuals frequently drop a large proportion of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments should be aware of the potential of rapid rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment mass within about 18 months.
Weighing Approaches
The analysis, which looked at 37 of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who shed pounds through lifestyle changes alone generally see a less rapid creep back—perhaps 100 grams monthly—after stopping.
Understanding the Fast Regain
Doctors propose the way of the injections accounts for the heightened regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone levels several times higher than normal might result in the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to hunger is uncontrolled, making excessive eating much more probable."
A Chronic Disease?
The NHS suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, considering the high risk of weight regain, the therapy should be considered ongoing.
This perspective is reinforced by drug manufacturers, who state that the findings "highlight the persistent nature of obesity," comparing it to managing diseases like hypertension.
Patient Accounts
People who have come off the medication explain a sudden resurgence of hunger.
"I experienced a trigger activating and you're instantly extremely hungry," described one woman.
This difficulty is compounded if users have not developed sustainable dietary or behavioural modifications during therapy.
Significant Interest
Recent estimates show that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is higher among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while the jabs are powerful agents for weight loss, they are not a permanent fix and maintained weight loss hinges on ongoing behavioural management.
